{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidwagdp56zao75ietlhljavsr43dqrrnxhqeds44gtywzn7vatjyi",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mf52aejwslw2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreierxcgnkny7zkfsn6rwsijnkdy5cxxqfnojsw46j7cnrdn3b27sbq"
    },
    "mimeType": "image/jpeg",
    "size": 229287
  },
  "path": "/news/2026-02-fda-noninvasive-optune-pax-device.html",
  "publishedAt": "2026-02-18T07:00:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of Optune Pax was granted to Novocure.",
  "title": "FDA approves noninvasive Optune Pax device for advanced pancreatic cancer"
}